Wells Fargo analyst Gabe Hajde raised the firm’s price target on AptarGroup to $160 from $157 and keeps an Overweight rating on the shares. The firm remains optimistic on AptarGroup’s positive earnings momentum with stable HSD growth in Pharma and an impending recovery in North America Beauty markets. Over the long-term, Wells believes AptarGroup’s pharma-centric portfolio and growth algorithm should support above-peer returns.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATR:
- AptarGroup price target raised to $157 from $152 at Wells Fargo
- Bad News for AptarGroup, Inc. Stock: This New Risk Has Been Added
- Aptar Digital Health enters enterprise agreement with Biogen
- AptarGroup sees Q1 EPS $1.10-$1.18, consensus $1.12
- AptarGroup reports Q4 adjusted EPS $1.21, consensus $1.12
